Joseph G. Pressey · Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
Follow
Article1 min read·Published Oct 2020Older

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Oct 2020 · 1 min read

In brief

In brief

Phase 2 international trial evaluating tazemetostat, an oral EZH2 inhibitor, in patients with advanced epithelioid sarcoma characterized by INI1/SMARCB1 loss. The study enrolled patients across nine countries to assess objective response rates and survival outcomes in this rare, aggressive soft-tissue malignancy with oncogenic dependence on EZH2.

Written by the GCMD Library team from the article.

Joseph G. Pressey

Background: Epithelioid sarcoma is a rare and aggressive soft-tissue sarcoma subtype. Over 90% of tumours have lost INI1 expression, leading to oncogenic dependence on the transcriptional repressor EZH2. In this study, we report the clinical activity and safety of tazemetostat, an oral selective EZH2 inhibitor, in patients with epithelioid sarcoma. Methods: In this open-label, phase 2 basket study, patients were enrolled from 32 hospitals and clinics in Australia, Belgium, Canada, France, Germany, Italy, Taiwan, the USA, and the UK into seven cohorts of patients with different INI1-negative solid tumours or synovial sarcoma. Patients eligible for the epithelioid sarcoma cohort (cohort 5) were aged 16 years or older with histologically confirmed, locally advanced or metastatic epithelioid sarcoma; documented loss of INI1 expression by immunohistochemical analysis or biallelic SMARCB1 (the gene that encodes INI1) alterations, or both; and an Eastern Cooperative Oncology Group performance status score of 0-2. Patients received 800 mg tazemetostat orally twice per day in continuous 28-day cycles until disease progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint was investigator-assessed objective response rate measured according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary endpoints were duration of response, disease control rate at 32 weeks, progression-free survival, overall survival, and pharmacokinetic and pharmacod

Statements in this article

  1. Over 90% of epithelioid sarcomas have lost INI1 expression, leading to oncogenic dependence on the transcriptional repressor EZH2.

    EstablishedBackground
  2. Eligible patients were aged 16 years or older with histologically confirmed, locally advanced or metastatic epithelioid sarcoma.

    GuidelineMethods
  3. Patients required documented loss of INI1 expression by immunohistochemical analysis or biallelic SMARCB1 alterations, or both.

    GuidelineMethods
  4. Eligible patients had an Eastern Cooperative Oncology Group performance status score of 0-2.

    GuidelineMethods
  5. Patients received 800 mg tazemetostat orally twice per day in continuous 28-day cycles until disease progression, unacceptable toxicity, or withdrawal of consent.

    RecommendationMethods
  6. The primary endpoint was investigator-assessed objective response rate measured according to the Response Evaluation Criteria in Solid Tumors, version 1.1.

    GuidelineMethods

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.